Retina degeneration is one of the major causes of blindness and visual impairment in the world, with millions of patients affected by diseases such as age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR) and inherited retinal diseases (IRD). Although the recent progress in gene therapy has made treatments to prevent and slow retina degeneration more accessible, there are currently no effective therapies to restore vision once the retina has degenerated. Regenerative strategies such as cell-based therapies using stem cell-derived retinal neurons represent a promising avenue to regenerate the retina and restore vision. However, despite the promising results in pre-clinical research, there are currently no approved therapies to regenerate the retina. Cell-based treatments still have some hurdles to overcome before progressing into the clinics. For instance, it remains unclear whether the transplanted cells can integrate into the retinal circuit and achieve functional improvements in the long-term. Additionally, material exchange between transplanted and host cells such as photoreceptors has represented a big challenge for therapies using stem cells to regenerate the retina. Recently, in vivo direct reprogramming of Müller glia into retinal neurons has emerged as an alternative approach to overcome the limitations associated with transplantation. Müller cells are an attractive target for regenerative therapies, as these cells have shown different degrees of regenerative capacity in vertebrates such as fish, chicken and mice. Notably, the Müller glia of teleost fish can dedifferentiate into retinal progenitors and regenerate the retina upon injury. Therefore, numerous studies have focused on the identification of genes and molecules that can potentiate the regenerative capacity of Müller glia in mammals. This chapter reviews the progress of pre-clinical research using cellular reprogramming to regenerate the retina, and it highlights the potential of using cellular reprogramming technologies to treat the major retinal degenerative diseases.